Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-10-21
2000-03-07
MacMillan, Keith D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514331, 514428, 514213, 514582, 514585, A61K 31445, A61K 3146, A61K 3140
Patent
active
060341025
ABSTRACT:
A method of treating atherosclerosis, independent of lipid lowering, in mammals, including humans, in need of treatment by inhibiting progression of an atherogenic lesion or by stabilizing plaque. Such lesion progression inhibition or plaque stabilization is preferably achieved by directly inhibiting chemokine expression leading to excessive inflammatory cell recruitment by administering a therapeutically effective amount of a compound of formula I.
REFERENCES:
patent: 5047431 (1991-09-01), Schickaneder et al.
patent: 5254594 (1993-10-01), Niikura et al.
patent: 5426123 (1995-06-01), Fontana
patent: 5552412 (1996-09-01), Cameron et al.
Helen Wiseman, The Antioxidant Action of a Pure antioestrogen: Ability to inhibit Lipid Peroxidation Compared to tamoxifen and 17.beta.-oestradiol and Relevenance to its Anticancer Potential, vol. 47, No. 3, Biochemical Pharmacology, pp. 493-498, 1994.
Tiina Saatro, et al., Antiatherogenic Effects of Adjuvant Antiestrogens: A Randomized Trial Comparing the Effects of Tamoxifen and Toremifene on Plasma Lipid Levels in Postmenopausal Women with Node-Positive Breast Cancer, Journal of Clinical Oncology, vol. 14, No. 2 (Feb.), 1996: pp. 429-433.
Maija Kaartinen, et al., Accumulation of Activated Mast Cells in the Shoulder Region of Human Coronary Atheroma, the Predilection Site of Atheromatous Rupture, vol. 90, No. 4, Circulation, pp. 1669-1678, Oct. 1994.
Valentin Fuster, Mechanisms Leading to Myocardial Infarction: Insights from Studies of Vascular Biology, vol. 90, No. 4, Circulation, pp. 2126-2146, Oct. 1994.
Helen Wiseman, et al., Tamoxifen Inhibits Lipid peroxidation in Cardiac Microsomes, vol. 45, No. 9 Biochemical Pharmacology, pp. 1851-1855, 1993.
C. J. Schwartz, et al., The Pathogenesis of Atherosclerosis: An Overview, vol. 14, Clin. Cardiol., pp. I-1--I-16, Feb. 1991.
M. R. Frazier'Jessen, et al., Estrogen Modulation of JE/Monocyte Chemoattractant Protein-1 mRNA Expression in Murine Macrophages, Journal of Immunology, vol. 154, No. 4, pp. 1838-1844, 1995.
David J. Grainer, et al., Tamoxifen Elevates Transforming Growth Factor-.beta. and Suppresses Diet-induced Formation of Lipid Lesions in Mouse Aorta, vol. 1, No. 10, Nature Medicine, pp. 1067-1073, Oct. 1995.
Helen Wisemam, et al., Droloxifene (3-hydroxytamoxifen) has Membrane Antioxidant Ability: Potential Relevance to its Mechanism of Therapeutic Action in Breast Cancer, 66, Cancer Letters, pp. 61-68, 1992.
Benson Gregg C.
Collier Steven W.
MacMillan Keith D.
Pfizer Inc
Richardson Peter C.
LandOfFree
Atherosclerosis treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Atherosclerosis treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Atherosclerosis treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-363490